ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Jeil Pharmaceutical, AstraZeneca and Merck side by side

Their registered studies and the programs behind them, as ClinicalTrials.gov shows them and the companies' own pipelines name them. Counts, not rankings: the companies differ in size, so each number is shown beside its share of that company's own programs.

Jeil Pharmaceutical×AstraZeneca×Merck×Three at a time for now; Pro will compare up to ten.

At a glance

Studies each sponsor leads, with the companies grouped under it. Every number opens the studies it counts.

Jeil PharmaceuticalAstraZenecaMerck
studies on the registry574,1972,455
open to participants now12298146
phase 3 studies under way4200112
reach primary completion within a year116859
programswith a study of their own in two years4119+5 named only84

Pipeline by phase

Each program once, at the furthest phase its own studies reached. The bar is the share of that company's programs, so a small company and a large one read on the same scale.

Furthest phaseJeil PharmaceuticalAstraZenecaMerck
Phase 1

Jeil Pharmaceutical: 1 of its 4 programs at phase 1

  1. JLP-2302phase 1
25%

AstraZeneca: 25 of its 119 programs at phase 1

  1. AZD4954phase 1
  2. AZD1613phase 1
  3. AZD1390phase 1
  4. Actinium Ac 225-DOTA-Anti-STEAP2 Monoclonal Antibody AZD2284phase 1
  5. ALXN2230phase 1

and 20 more — sign in to see them all

21%

Merck: 27 of its 84 programs at phase 1

  1. MK4646phase 1
  2. F-2phase 1
  3. MK-7602phase 1
  4. V118Cphase 1
  5. MK-4716phase 1

and 22 more — sign in to see them all

32%
Phase 2

Jeil Pharmaceutical: 2 of its 4 programs at phase 2

  1. nesuparibphase 2
  2. Bevacizumabphase 2
50%

AstraZeneca: 47 of its 119 programs at phase 2

  1. AZD9550phase 2
  2. zadavotide guraxetanphase 2
  3. palacaparibphase 2
  4. Berzanoflastphase 2
  5. AZD7798phase 2

and 42 more — sign in to see them all

39%
23%
Phase 3

Jeil Pharmaceutical: 1 of its 4 programs at phase 3

  1. zastaprazanphase 3
25%

AstraZeneca: 28 of its 119 programs at phase 3

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3

and 23 more — sign in to see them all

24%

Merck: 35 of its 84 programs at phase 3

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. tulisokibartphase 3
  4. ifinatamab deruxtecanphase 3
  5. intismeran autogenephase 3

and 30 more — sign in to see them all

42%
Approved, new studies00%

AstraZeneca: 19 of its 119 programs at approved, new studies

  1. durvalumabapproved, new study
  2. acalabrutinibapproved, new study
  3. trastuzumab deruxtecanapproved, new study
  4. osimertinibapproved, new study
  5. anifrolumabapproved, new study

and 14 more — sign in to see them all

16%

Merck: 3 of its 84 programs at approved, new studies

  1. pembrolizumabapproved, new study
  2. sotaterceptapproved, new study
  3. Metforminapproved, new study
4%

Readouts ahead

Programs whose next study reaches primary completion in each month, by the sponsor's own estimate. A ring marks a month with a phase 3 readout.

Nov ’26DecJan ’27FebMarAprMayJunJulAugSepOct
Jeil Pharmaceutical1 readouts · 1 phase 3·········

Jeil Pharmaceutical, Aug ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zastaprazanphase 3 · Aug 0 · NCT06439563
··
AstraZeneca60 readouts · 16 phase 3

AstraZeneca, Nov ’26: 4 programs whose next study reaches primary completion

  1. Autologous dnTGF-BRII-armored Anti-STEAP2 CAR T-cells AZD0754phase 2 · Nov 24 · NCT06267729
  2. STEAP2-targeting Radioconjugate AZD2287phase 2 · Nov 24 · NCT06267729
  3. durvalumabapproved, new study · Nov 30 · NCT07081633
  4. tremelimumabphase 3 · Nov 30 · NCT07081633

AstraZeneca, Dec ’26: 7 programs whose next study reaches primary completion, 2 in phase 3

  1. eculizumabapproved, new study · Dec 7 · NCT06724809
  2. AZD3974phase 1 · Dec 8 · NCT07290283
  3. baxdrostatphase 3 · Dec 10 · NCT07222917
  4. dapagliflozinapproved, new study · Dec 10 · NCT07222917
  5. benralizumabapproved, new study · Dec 23 · NCT05692180

and 2 more — sign in to see them all

AstraZeneca, Jan ’27: 13 programs whose next study reaches primary completion, 6 in phase 3

  1. laroprovstatphase 3 · Jan 4 · NCT07000136
  2. anifrolumabapproved, new study · Jan 6 · NCT05925803
  3. monalizumabphase 3 · Jan 8 · NCT05221840
  4. oleclumabphase 3 · Jan 8 · NCT05221840
  5. datopotamab deruxtecanphase 3 · Jan 11 · NCT06417814

and 8 more — sign in to see them all

AstraZeneca, Feb ’27: 7 programs whose next study reaches primary completion, 3 in phase 3

  1. Autologous Bispecific BCMA/CD19-targeted CAR-T Cells GC012Fphase 3 · Feb 1 · NCT06530849
  2. trastuzumab deruxtecanapproved, new study · Feb 10 · NCT06271837
  3. Berzanoflastphase 2 · Feb 11 · NCT07215702
  4. acalabrutinibapproved, new study · Feb 15 · NCT02972840
  5. zibotentanphase 3 · Feb 18 · NCT06087835

and 2 more — sign in to see them all

AstraZeneca, Mar ’27: 4 programs whose next study reaches primary completion

  1. AZD7760phase 2 · Mar 8 · NCT06749457
  2. AZD4954phase 1 · Mar 17 · NCT07812077
  3. AZD0543phase 1 · Mar 24 · NCT07824622
  4. Anti-Claudin 18.2 Antibody-drug Conjugate AZD4360phase 2 · Mar 31 · NCT06921928

AstraZeneca, Apr ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. AZD1043phase 1 · Apr 9 · NCT07511205
  2. camizestrantphase 3 · Apr 20 · NCT05774951
  3. ombetoxabartphase 2 · Apr 20 · NCT07285213

AstraZeneca, May ’27: 5 programs whose next study reaches primary completion, 2 in phase 3

  1. rilvegostomigphase 3 · May 4 · NCT04379596
  2. Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492phase 2 · May 5 · NCT06916806
  3. AZD1613phase 1 · May 22 · NCT07228364
  4. Budesonideapproved, new study · May 31 · NCT07073950
  5. formoterolapproved, new study · May 31 · NCT07073950

AstraZeneca, Jun ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. tozorakimabphase 3 · Jun 7 · NCT06932263
  2. ravulizumabapproved, new study · Jun 25 · NCT07308574
  3. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2 · Jun 30 · NCT06795022

AstraZeneca, Jul ’27: 3 programs whose next study reaches primary completion

  1. ALXN1920phase 2 · Jul 2 · NCT07157787
  2. AZD2389phase 2 · Jul 7 · NCT07610837
  3. SC rilvegostomig + rHuphase 1 · Jul 19 · NCT07161414

AstraZeneca, Aug ’27: 4 programs whose next study reaches primary completion

  1. ALXN2230phase 1 · Aug 9 · NCT07352423
  2. AZD0240phase 1 · Aug 30 · NCT06218914
  3. SC durvalumab + rHuphase 1 · Aug 30 · NCT07391670
  4. AZD6793phase 2 · Aug 31 · NCT07082738

AstraZeneca, Sep ’27: 2 programs whose next study reaches primary completion

  1. palacaparibphase 2 · Sep 29 · NCT05123482
  2. puxitatug samrotecanphase 3 · Sep 29 · NCT05123482

AstraZeneca, Oct ’27: 5 programs whose next study reaches primary completion, 1 in phase 3

  1. opemalirsenphase 2 · Oct 4 · NCT06824987
  2. cevolisiranphase 2 · Oct 11 · NCT06744647
  3. tarperprumigphase 2 · Oct 11 · NCT07160608
  4. torvutatug samrotecanphase 3 · Oct 15 · NCT07402915
  5. sodium zirconium cyclosilicateapproved, new study · Oct 30 · NCT07944378
Merck25 readouts · 6 phase 3·

Merck, Dec ’26: 3 programs whose next study reaches primary completion

  1. enlicitide chloridephase 3 · Dec 14 · NCT07776665
  2. F-2phase 1 · Dec 15 · NCT07748351
  3. efitazanamivir alfaphase 3 · Dec 31 · NCT07300085

Merck, Jan ’27: 4 programs whose next study reaches primary completion, 3 in phase 3

  1. remigromigphase 3 · Jan 11 · NCT06957080
  2. Human Papillomavirus Recombinant Vaccine nonavalentphase 3 · Jan 15 · NCT04199689
  3. alimatravirphase 3 · Jan 19 · NCT07600775
  4. pembrolizumabapproved, new study · Jan 31 · NCT04241185

Merck, Feb ’27: 4 programs whose next study reaches primary completion

  1. nemtabrutinibphase 3 · Feb 1 · NCT07734610
  2. MK-6916phase 2 · Feb 9 · NCT07862621
  3. tulisokibartphase 3 · Feb 17 · NCT07486960
  4. belzutifanphase 3 · Feb 26 · NCT03634540

Merck, Mar ’27: 1 program whose next study reaches primary completion

  1. ensifentrinephase 3 · Mar 1 · NCT05270525

Merck, Apr ’27: 3 programs whose next study reaches primary completion

  1. MK-7602phase 1 · Apr 5 · NCT07919028
  2. pyronaridinephase 1 · Apr 5 · NCT07919028
  3. intismeran autogenephase 3 · Apr 23 · NCT06305767

Merck, May ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. sacituzumab tirumotecanphase 3 · May 10 · NCT06074588

Merck, Jun ’27: 2 programs whose next study reaches primary completion

  1. ifinatamab deruxtecanphase 3 · Jun 12 · NCT07405151
  2. ulonivirinephase 3 · Jun 29 · NCT05093972

Merck, Jul ’27: 3 programs whose next study reaches primary completion, 1 in phase 3

  1. V118Ephase 1 · Jul 6 · NCT07168915
  2. bomedemstatphase 3 · Jul 14 · NCT06079879
  3. Anti-nectin-4 Antibody-drug Conjugate MK-3120phase 2 · Jul 30 · NCT07222488

Merck, Aug ’27: 1 program whose next study reaches primary completion

  1. islatravirphase 3 · Aug 10 · NCT06891066

Merck, Sep ’27: 1 program whose next study reaches primary completion, 1 in phase 3

  1. zilovertamab vedotinphase 3 · Sep 24 · NCT05139017

Merck, Oct ’27: 2 programs whose next study reaches primary completion

  1. HRS-5346phase 2 · Oct 12 · NCT07614984
  2. MK-8690phase 2 · Oct 19 · NCT07895524
size: programs that monthincludes phase 3Dates are estimates the sponsors file and often move.

Changed in the last 90 days

Since Aug 23, 2026: programs whose first study was registered, programs that reached a new phase, studies stopped, and primary completions moved later (a month or more in phase 3, three otherwise). Stops and dates are read from the registry’s changes, kept since Sep 25, 2026.

Jeil Pharmaceutical

New programs 0

None

Reached a new phase 0

None

Study stopped 0

None

Primary completion later 0

None

AstraZeneca

New programs 2

Reached a new phase 1

Study stopped 0

None

Primary completion later 23

Merck

New programs 7

  • V951Aphase 1 · first study · Nov 10
  • pyronaridinephase 1 · first study · Oct 30 · Malaria, Falciparum
  • MK-2750phase 2 · first study · Oct 9 · Neoplasms
  • MK-6255phase 1 · first study · Oct 6 · Ovarian Neoplasms
  • V175phase 1 · first study · Sep 28
  • V175Aphase 1 · first study · Sep 28
  • Merck: new programs in 90 days

    1. V951Aphase 1 · first study · Nov 10
    2. pyronaridinephase 1 · first study · Oct 30
    3. MK-2750phase 2 · first study · Oct 9
    4. MK-6255phase 1 · first study · Oct 6
    5. V175phase 1 · first study · Sep 28

    and 2 more — sign in to see them all

Reached a new phase 2

  • gocatamigphase 3 · Oct 26 · Small Cell Lung Carcinoma
  • MK-6916phase 2 · Oct 2 · Renal Insufficiency

Study stopped 4

Primary completion later 6

Where they overlap

Conditions where at least two of them have programs: 50 in all. A program counts in each condition its studies name most.

ConditionJeil PharmaceuticalAstraZenecaMerck
Carcinoma, Non-Small-Cell Lungall three · compare here

Jeil Pharmaceutical in Carcinoma, Non-Small-Cell Lung: 1 program

  1. Bevacizumabphase 2

Their studies: Jeil Pharmaceutical’s studies of Carcinoma, Non-Small-Cell Lung in search

AstraZeneca in Carcinoma, Non-Small-Cell Lung: 16 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. tremelimumabphase 3
  4. volrustomigphase 3
  5. ceralasertibphase 3

and 11 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Non-Small-Cell Lung in search

Merck in Carcinoma, Non-Small-Cell Lung: 10 programs

  1. sacituzumab tirumotecanphase 3
  2. ifinatamab deruxtecanphase 3
  3. intismeran autogenephase 3
  4. patritumab deruxtecanphase 3
  5. calderasibphase 3

and 5 more — sign in to see them all

Their studies: Merck’s studies of Carcinoma, Non-Small-Cell Lung in search

Breast Neoplasmsall three · compare here

Jeil Pharmaceutical in Breast Neoplasms: 1 program

  1. Bevacizumabphase 2

Their studies: Jeil Pharmaceutical’s studies of Breast Neoplasms in search

AstraZeneca in Breast Neoplasms: 10 programs

  1. datopotamab deruxtecanphase 3
  2. saruparibphase 3
  3. capivasertibphase 3
  4. camizestrantphase 3
  5. puxitatug samrotecanphase 3

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Breast Neoplasms in search

Merck in Breast Neoplasms: 3 programs

  1. sacituzumab tirumotecanphase 3
  2. belzutifanphase 3
  3. patritumab deruxtecanphase 3

Their studies: Merck’s studies of Breast Neoplasms in search

Stomach Neoplasmsall three · compare here

Jeil Pharmaceutical in Stomach Neoplasms: 1 program

  1. nesuparibphase 2

Their studies: Jeil Pharmaceutical’s studies of Stomach Neoplasms in search

Merck in Stomach Neoplasms: 1 program

  1. pembrolizumabapproved, new study

Their studies: Merck’s studies of Stomach Neoplasms in search

Ovarian Neoplasmsall three · compare here

Jeil Pharmaceutical in Ovarian Neoplasms: 2 programs

  1. nesuparibphase 2
  2. Bevacizumabphase 2

Their studies: Jeil Pharmaceutical’s studies of Ovarian Neoplasms in search

AstraZeneca in Ovarian Neoplasms: 2 programs

  1. saruparibphase 3
  2. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Ovarian Neoplasms in search

Colorectal Neoplasmsall three · compare here

Jeil Pharmaceutical in Colorectal Neoplasms: 1 program

  1. Bevacizumabphase 2

Their studies: Jeil Pharmaceutical’s studies of Colorectal Neoplasms in search

AstraZeneca in Colorectal Neoplasms: 1 program

  1. Leucovorinphase 2

Their studies: AstraZeneca’s studies of Colorectal Neoplasms in search

Merck in Colorectal Neoplasms: 2 programs

  1. zanzalintinibphase 3
  2. Cetuximabphase 3

Their studies: Merck’s studies of Colorectal Neoplasms in search

Neoplasms2 of 3 · compare here–

AstraZeneca in Neoplasms: 6 programs

  1. saruparibphase 3
  2. ceralasertibphase 3
  3. Leucovorinphase 2
  4. Ramucirumabphase 2
  5. AZD1390phase 1

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Neoplasms in search

Merck in Neoplasms: 14 programs

  1. belzutifanphase 3
  2. ifinatamab deruxtecanphase 3
  3. patritumab deruxtecanphase 3
  4. calderasibphase 3
  5. opevesostatphase 3

and 9 more — sign in to see them all

Their studies: Merck’s studies of Neoplasms in search

Renal Insufficiency2 of 3 · compare here–

AstraZeneca in Renal Insufficiency: 8 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. zibotentanphase 3
  4. balcinrenonephase 3
  5. opemalirsenphase 2

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Renal Insufficiency in search

Merck in Renal Insufficiency: 7 programs

  1. calderasibphase 3
  2. nemtabrutinibphase 3
  3. alimatravirphase 3
  4. enlicitide chloridephase 3
  5. doravirinephase 3

and 2 more — sign in to see them all

Their studies: Merck’s studies of Renal Insufficiency in search

Prostatic Neoplasms2 of 3 · compare here–

AstraZeneca in Prostatic Neoplasms: 13 programs

  1. saruparibphase 3
  2. capivasertibphase 3
  3. zibotentanphase 3
  4. Actinium-225phase 3
  5. zadavotide guraxetanphase 2

and 8 more — sign in to see them all

Their studies: AstraZeneca’s studies of Prostatic Neoplasms in search

Merck in Prostatic Neoplasms: 1 program

  1. opevesostatphase 3

Their studies: Merck’s studies of Prostatic Neoplasms in search

Asthma2 of 3 · compare here–

AstraZeneca in Asthma: 10 programs

  1. tozorakimabphase 3
  2. BFF MDIphase 3
  3. GP MDIphase 3
  4. londamocitinibphase 2
  5. sunakimentphase 2

and 5 more — sign in to see them all

Their studies: AstraZeneca’s studies of Asthma in search

Merck in Asthma: 1 program

  1. ensifentrinephase 3

Their studies: Merck’s studies of Asthma in search

Diabetes Mellitus, Type 22 of 3 · compare here–

AstraZeneca in Diabetes Mellitus, Type 2: 5 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD6793phase 2
  4. Elecoglipron Test formulation 1 Dose Aphase 1
  5. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus, Type 2 in search

Merck in Diabetes Mellitus, Type 2: 4 programs

  1. efinopegdutidephase 2
  2. MK-1403phase 1
  3. MK-2828phase 1
  4. Metforminapproved, new study

Their studies: Merck’s studies of Diabetes Mellitus, Type 2 in search

Pulmonary Disease, Chronic Obstructive2 of 3 · compare here–

AstraZeneca in Pulmonary Disease, Chronic Obstructive: 8 programs

  1. tozorakimabphase 3
  2. GP MDIphase 3
  3. AZD6793phase 2
  4. Treatment A: BGF MDI HFOphase 1
  5. tezepelumabapproved, new study

and 3 more — sign in to see them all

Their studies: AstraZeneca’s studies of Pulmonary Disease, Chronic Obstructive in search

Merck in Pulmonary Disease, Chronic Obstructive: 1 program

  1. ensifentrinephase 3

Their studies: Merck’s studies of Pulmonary Disease, Chronic Obstructive in search

Leukemia, Lymphocytic, Chronic, B-Cell2 of 3 · compare here–

AstraZeneca in Leukemia, Lymphocytic, Chronic, B-Cell: 5 programs

  1. surovatamigphase 3
  2. ceralasertibphase 3
  3. monalizumabphase 3
  4. pirtobrutinibphase 2
  5. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Merck in Leukemia, Lymphocytic, Chronic, B-Cell: 3 programs

  1. Anti-CD19/CD3 Bispecific Antibody MK-1045phase 3
  2. nemtabrutinibphase 3
  3. zilovertamab vedotinphase 3

Their studies: Merck’s studies of Leukemia, Lymphocytic, Chronic, B-Cell in search

Carcinoma, Hepatocellular2 of 3 · compare here

Jeil Pharmaceutical in Carcinoma, Hepatocellular: 1 program

  1. Bevacizumabphase 2

Their studies: Jeil Pharmaceutical’s studies of Carcinoma, Hepatocellular in search

AstraZeneca in Carcinoma, Hepatocellular: 6 programs

  1. rilvegostomigphase 3
  2. tremelimumabphase 3
  3. Leucovorinphase 2
  4. Anti-GPC3 T Cell-engaging Antibody AZD9793phase 2
  5. Ramucirumabphase 2

and 1 more — sign in to see them all

Their studies: AstraZeneca’s studies of Carcinoma, Hepatocellular in search

–
Carcinoma, Renal Cell2 of 3 · compare here–

AstraZeneca in Carcinoma, Renal Cell: 3 programs

  1. volrustomigphase 3
  2. Actinium-225phase 3
  3. casdatifanphase 1

Their studies: AstraZeneca’s studies of Carcinoma, Renal Cell in search

Merck in Carcinoma, Renal Cell: 4 programs

  1. belzutifanphase 3
  2. intismeran autogenephase 3
  3. raludotatug deruxtecanphase 3
  4. zanzalintinibphase 3

Their studies: Merck’s studies of Carcinoma, Renal Cell in search

Obesity2 of 3 · compare here–

AstraZeneca in Obesity: 4 programs

  1. elecoglipronphase 3
  2. lenbelintidephase 3
  3. AZD9550phase 2
  4. AZD1043phase 1

Their studies: AstraZeneca’s studies of Obesity in search

Merck in Obesity: 3 programs

  1. efinopegdutidephase 2
  2. TERN-601phase 2
  3. Metforminapproved, new study

Their studies: Merck’s studies of Obesity in search

Triple Negative Breast Neoplasms2 of 3 · compare here–

AstraZeneca in Triple Negative Breast Neoplasms: 4 programs

  1. datopotamab deruxtecanphase 3
  2. capivasertibphase 3
  3. ceralasertibphase 3
  4. Actinium-225phase 3

Their studies: AstraZeneca’s studies of Triple Negative Breast Neoplasms in search

Merck in Triple Negative Breast Neoplasms: 3 programs

  1. sacituzumab tirumotecanphase 3
  2. zilovertamab vedotinphase 3
  3. boserolimabphase 2

Their studies: Merck’s studies of Triple Negative Breast Neoplasms in search

Kidney Failure, Chronic2 of 3 · compare here–

AstraZeneca in Kidney Failure, Chronic: 1 program

  1. Berzanoflastphase 2

Their studies: AstraZeneca’s studies of Kidney Failure, Chronic in search

Merck in Kidney Failure, Chronic: 5 programs

  1. opevesostatphase 3
  2. efinopegdutidephase 2
  3. MK-2060phase 2
  4. MK-2828phase 1
  5. bictegravirphase 1

Their studies: Merck’s studies of Kidney Failure, Chronic in search

Lymphoma, Follicular2 of 3 · compare here–

AstraZeneca in Lymphoma, Follicular: 5 programs

  1. surovatamigphase 3
  2. camizestrantphase 3
  3. lenbelintidephase 3
  4. AZD9550phase 2
  5. AZD2389phase 2

Their studies: AstraZeneca’s studies of Lymphoma, Follicular in search

Merck in Lymphoma, Follicular: 1 program

  1. Anti-CD19/CD3 Bispecific Antibody MK-1045phase 3

Their studies: Merck’s studies of Lymphoma, Follicular in search

Melanoma2 of 3 · compare here–

AstraZeneca in Melanoma: 3 programs

  1. tremelimumabphase 3
  2. ceralasertibphase 3
  3. CD8-guided IL-2 Fusion Protein AZD6750phase 2

Their studies: AstraZeneca’s studies of Melanoma in search

Merck in Melanoma: 3 programs

  1. intismeran autogenephase 3
  2. BCG Vaccinephase 2
  3. pembrolizumabapproved, new study

Their studies: Merck’s studies of Melanoma in search

Endometrial Neoplasms2 of 3 · compare here–

AstraZeneca in Endometrial Neoplasms: 4 programs

  1. rilvegostomigphase 3
  2. datopotamab deruxtecanphase 3
  3. puxitatug samrotecanphase 3
  4. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Endometrial Neoplasms in search

Merck in Endometrial Neoplasms: 1 program

  1. sacituzumab tirumotecanphase 3

Their studies: Merck’s studies of Endometrial Neoplasms in search

Hepatic Insufficiency2 of 3 · compare here–

AstraZeneca in Hepatic Insufficiency: 2 programs

  1. atirmociclibphase 2
  2. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Hepatic Insufficiency in search

Merck in Hepatic Insufficiency: 3 programs

  1. bomedemstatphase 3
  2. ulonivirinephase 3
  3. enlicitide chloridephase 3

Their studies: Merck’s studies of Hepatic Insufficiency in search

Hypercholesterolemia2 of 3 · compare here–

AstraZeneca in Hypercholesterolemia: 2 programs

  1. laroprovstatphase 3
  2. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hypercholesterolemia in search

Merck in Hypercholesterolemia: 3 programs

  1. enlicitide decanoatephase 3
  2. enlicitide chloridephase 3
  3. rosuvastatinphase 3

Their studies: Merck’s studies of Hypercholesterolemia in search

Hyperlipidemias2 of 3 · compare here–

AstraZeneca in Hyperlipidemias: 3 programs

  1. laroprovstatphase 3
  2. Laroprovstat/ezetimibe FCDP-slow variantphase 1
  3. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hyperlipidemias in search

Merck in Hyperlipidemias: 2 programs

  1. enlicitide chloridephase 3
  2. rosuvastatinphase 3

Their studies: Merck’s studies of Hyperlipidemias in search

Multiple Myeloma2 of 3 · compare here–

Merck in Multiple Myeloma: 1 program

  1. sotaterceptapproved, new study

Their studies: Merck’s studies of Multiple Myeloma in search

Small Cell Lung Carcinoma2 of 3 · compare here–

AstraZeneca in Small Cell Lung Carcinoma: 2 programs

  1. tremelimumabphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Small Cell Lung Carcinoma in search

Merck in Small Cell Lung Carcinoma: 3 programs

  1. ifinatamab deruxtecanphase 3
  2. gocatamigphase 3
  3. boserolimabphase 2

Their studies: Merck’s studies of Small Cell Lung Carcinoma in search

Squamous Cell Carcinoma of Head and Neck2 of 3 · compare here–

AstraZeneca in Squamous Cell Carcinoma of Head and Neck: 3 programs

  1. tremelimumabphase 3
  2. volrustomigphase 3
  3. monalizumabphase 3

Their studies: AstraZeneca’s studies of Squamous Cell Carcinoma of Head and Neck in search

Merck in Squamous Cell Carcinoma of Head and Neck: 2 programs

  1. Cetuximabphase 3
  2. pembrolizumabapproved, new study

Their studies: Merck’s studies of Squamous Cell Carcinoma of Head and Neck in search

Urinary Bladder Neoplasms2 of 3 · compare here–

AstraZeneca in Urinary Bladder Neoplasms: 2 programs

  1. datopotamab deruxtecanphase 3
  2. durvalumabapproved, new study

Their studies: AstraZeneca’s studies of Urinary Bladder Neoplasms in search

Merck in Urinary Bladder Neoplasms: 3 programs

  1. Anti-nectin-4 Antibody-drug Conjugate MK-3120phase 2
  2. BCG Vaccinephase 2
  3. pembrolizumabapproved, new study

Their studies: Merck’s studies of Urinary Bladder Neoplasms in search

Colitis, Ulcerative2 of 3 · compare here–

AstraZeneca in Colitis, Ulcerative: 1 program

  1. Budesonideapproved, new study

Their studies: AstraZeneca’s studies of Colitis, Ulcerative in search

Merck in Colitis, Ulcerative: 3 programs

  1. tulisokibartphase 3
  2. MK-8690phase 2
  3. MK-6194phase 2

Their studies: Merck’s studies of Colitis, Ulcerative in search

Dyslipidemias2 of 3 · compare here–

AstraZeneca in Dyslipidemias: 3 programs

  1. laroprovstatphase 3
  2. AZD4954phase 1
  3. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Dyslipidemias in search

Merck in Dyslipidemias: 1 program

  1. rosuvastatinphase 3

Their studies: Merck’s studies of Dyslipidemias in search

Lung Neoplasms2 of 3 · compare here–

AstraZeneca in Lung Neoplasms: 1 program

  1. osimertinibapproved, new study

Their studies: AstraZeneca’s studies of Lung Neoplasms in search

Merck in Lung Neoplasms: 3 programs

  1. ifinatamab deruxtecanphase 3
  2. raludotatug deruxtecanphase 3
  3. Rescue Medicationsphase 2

Their studies: Merck’s studies of Lung Neoplasms in search

Lupus Erythematosus, Systemic2 of 3 · compare here–

Merck in Lupus Erythematosus, Systemic: 1 program

  1. MK-6194phase 2

Their studies: Merck’s studies of Lupus Erythematosus, Systemic in search

Lymphoma, Large B-Cell, Diffuse2 of 3 · compare here–

AstraZeneca in Lymphoma, Large B-Cell, Diffuse: 1 program

  1. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of Lymphoma, Large B-Cell, Diffuse in search

Neoplasm Metastasis2 of 3 · compare here–

AstraZeneca in Neoplasm Metastasis: 3 programs

  1. saruparibphase 3
  2. camizestrantphase 3
  3. trastuzumab deruxtecanapproved, new study

Their studies: AstraZeneca’s studies of Neoplasm Metastasis in search

Merck in Neoplasm Metastasis: 1 program

  1. MK-8294phase 1

Their studies: Merck’s studies of Neoplasm Metastasis in search

Arthritis, Rheumatoid2 of 3 · compare here–

AstraZeneca in Arthritis, Rheumatoid: 2 programs

  1. surovatamigphase 3
  2. AZD1163phase 2

Their studies: AstraZeneca’s studies of Arthritis, Rheumatoid in search

Merck in Arthritis, Rheumatoid: 1 program

  1. MK-8690phase 2

Their studies: Merck’s studies of Arthritis, Rheumatoid in search

Burkitt Lymphoma2 of 3 · compare here–
Colonic Neoplasms2 of 3 · compare here–

AstraZeneca in Colonic Neoplasms: 2 programs

  1. oleclumabphase 3
  2. monalizumabphase 3

Their studies: AstraZeneca’s studies of Colonic Neoplasms in search

Merck in Colonic Neoplasms: 1 program

  1. calderasibphase 3

Their studies: Merck’s studies of Colonic Neoplasms in search

COVID-192 of 3 · compare here–

AstraZeneca in COVID-19: 1 program

  1. acalabrutinibapproved, new study

Their studies: AstraZeneca’s studies of COVID-19 in search

Merck in COVID-19: 2 programs

  1. molnupiravirphase 3
  2. frespaciguatphase 3

Their studies: Merck’s studies of COVID-19 in search

Hypertension2 of 3 · compare here–

AstraZeneca in Hypertension: 2 programs

  1. baxdrostatphase 3
  2. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Hypertension in search

Merck in Hypertension: 1 program

  1. rosuvastatinphase 3

Their studies: Merck’s studies of Hypertension in search

Influenza, Human2 of 3 · compare here–

AstraZeneca in Influenza, Human: 2 programs

  1. AZD4117phase 2
  2. AZD5315phase 2

Their studies: AstraZeneca’s studies of Influenza, Human in search

Merck in Influenza, Human: 1 program

  1. efitazanamivir alfaphase 3

Their studies: Merck’s studies of Influenza, Human in search

Coronary Artery Disease2 of 3 · compare here–

AstraZeneca in Coronary Artery Disease: 1 program

  1. rosuvastatinapproved, new study

Their studies: AstraZeneca’s studies of Coronary Artery Disease in search

Merck in Coronary Artery Disease: 1 program

  1. rosuvastatinphase 3

Their studies: Merck’s studies of Coronary Artery Disease in search

Crohn Disease2 of 3 · compare here–

AstraZeneca in Crohn Disease: 1 program

  1. AZD7798phase 2

Their studies: AstraZeneca’s studies of Crohn Disease in search

Merck in Crohn Disease: 1 program

  1. tulisokibartphase 3

Their studies: Merck’s studies of Crohn Disease in search

Dermatitis, Atopic2 of 3 · compare here–

AstraZeneca in Dermatitis, Atopic: 1 program

  1. tezepelumabapproved, new study

Their studies: AstraZeneca’s studies of Dermatitis, Atopic in search

Merck in Dermatitis, Atopic: 1 program

  1. MK-6194phase 2

Their studies: Merck’s studies of Dermatitis, Atopic in search

Diabetes Mellitus2 of 3 · compare here–

AstraZeneca in Diabetes Mellitus: 1 program

  1. dapagliflozinapproved, new study

Their studies: AstraZeneca’s studies of Diabetes Mellitus in search

Merck in Diabetes Mellitus: 1 program

  1. Metforminapproved, new study

Their studies: Merck’s studies of Diabetes Mellitus in search

Fallopian Tube Neoplasms2 of 3 · compare here–

AstraZeneca in Fallopian Tube Neoplasms: 1 program

  1. torvutatug samrotecanphase 3

Their studies: AstraZeneca’s studies of Fallopian Tube Neoplasms in search

Merck in Fallopian Tube Neoplasms: 1 program

  1. raludotatug deruxtecanphase 3

Their studies: Merck’s studies of Fallopian Tube Neoplasms in search

Fasting2 of 3 · compare here–

AstraZeneca in Fasting: 1 program

  1. balcinrenonephase 3

Their studies: AstraZeneca’s studies of Fasting in search

Merck in Fasting: 1 program

  1. Metforminapproved, new study

Their studies: Merck’s studies of Fasting in search

Head and Neck Neoplasms2 of 3 · compare here–

AstraZeneca in Head and Neck Neoplasms: 1 program

  1. monalizumabphase 3

Their studies: AstraZeneca’s studies of Head and Neck Neoplasms in search

Merck in Head and Neck Neoplasms: 1 program

  1. Cetuximabphase 3

Their studies: Merck’s studies of Head and Neck Neoplasms in search

Hematologic Neoplasms2 of 3 · compare here–

AstraZeneca in Hematologic Neoplasms: 1 program

  1. capivasertibphase 3

Their studies: AstraZeneca’s studies of Hematologic Neoplasms in search

Merck in Hematologic Neoplasms: 1 program

  1. nemtabrutinibphase 3

Their studies: Merck’s studies of Hematologic Neoplasms in search

Non-alcoholic Fatty Liver Disease2 of 3 · compare here–

AstraZeneca in Non-alcoholic Fatty Liver Disease: 1 program

  1. AZD9550phase 2

Their studies: AstraZeneca’s studies of Non-alcoholic Fatty Liver Disease in search

Merck in Non-alcoholic Fatty Liver Disease: 1 program

  1. efinopegdutidephase 2

Their studies: Merck’s studies of Non-alcoholic Fatty Liver Disease in search

Respiratory Syncytial Virus Infections2 of 3 · compare here–

AstraZeneca in Respiratory Syncytial Virus Infections: 1 program

  1. Palivizumabapproved, new study

Their studies: AstraZeneca’s studies of Respiratory Syncytial Virus Infections in search

Merck in Respiratory Syncytial Virus Infections: 1 program

  1. Pneumococcal 20-Valent Conjugate Vaccinephase 1

Their studies: Merck’s studies of Respiratory Syncytial Virus Infections in search

Uterine Cervical Neoplasms2 of 3 · compare here–

AstraZeneca in Uterine Cervical Neoplasms: 1 program

  1. volrustomigphase 3

Their studies: AstraZeneca’s studies of Uterine Cervical Neoplasms in search

Same targetBetaPro · free during the beta

Programs that act on the same gene, from the company’s own words, a judged reading of NCIt, ChEMBL or the studies, or a rule. A reading by rule is marked rule.

A target, or a pathogen for a vaccine, known for: Jeil Pharmaceutical 2 of 4 · AstraZeneca 68 of 119 · Merck 40 of 84 programs (44 of them by rule). Most early programs are named only by a code and their companies do not say what they act on, so this list is short and grows as targets are read.

What this can't show

  • Only what ClinicalTrials.gov holds: programs run only in other registries are missing.
  • Grouping is ours: subsidiaries and acquisitions counted under the parent, each dated and sourced on the sponsor page.
  • Readout dates are the sponsors’ estimates, not results.
  • A program is a drug as the registry names it: a code its company has not tied to a name counts on its own until it is read, and a study run under a partner’s name counts for the partner.
  • “Same target” covers only the programs whose target is known, from the company’s words, a judged reading or a rule; most early programs say nothing of it.
  • Programs a company names but has not registered are counted apart (AstraZeneca: 5).